Identification of natural compounds with antiviral activities against SARS-associated coronavirus

被引:527
作者
Li, SY
Chen, C
Zhang, HQ
Guo, HY
Wang, H
Wang, L
Zhang, X
Hua, SN
Yu, J
Xiao, PG
Li, RS
Tan, XH [1 ]
机构
[1] Chinese Acad Sci, Beijing Genom Inst, Beijing 101300, Peoples R China
[2] Beijing Univ Chinese Med, Sch Chinese Mat Med, Beijing 100102, Peoples R China
[3] HD Biosci Co Ltd, Shanghai 201203, Peoples R China
[4] Chinese Acad Med Sci, Inst Med Plant Dev, Beijing 100094, Peoples R China
[5] Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China
关键词
Severe Acute Respiratory Syndrome coronavirus (SARS-CoV); drug screening; natural products; lycorine; Lycoris radiata herb;
D O I
10.1016/j.antiviral.2005.02.007
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
More than 200 Chinese medicinal herb extracts were screened for antiviral activities against Severe Acute Respiratory Syndrome-associated coronavirus (SARS-CoV) using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (NITS) assay for virus-induced cytopathic effect (CPE). Four of these extracts showed moderate to potent antiviral activities against SARS-CoV with 50% effective concentration (EC50) ranging from 2.4 +/- 0.2 to 88.2 +/- 7.7 mu g/ml. Out of the four, Lycoris radiata was most potent. To identify the active component, L. radiata extract was subjected to further fractionation, purification, and CPE/MTS assays. This process led to the identification of a single substance lycorine as an anti-SARS-CoV component with an EC50 value of 15.7 +/- 1.2 nM. This compound has a CC50 value of 14980.0 +/- 912.0 nM in cytotoxicity assay and a selective index (SI) greater than 900. The results suggested that four herbal extracts and the compound lycorine are candidates for the development of new anti-SARS-CoV drugs in the treatment of SARS. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:18 / 23
页数:6
相关论文
共 29 条
[1]
THE ALKALOIDS OF CRINUM-AUGUSTUM .1. 2 NON-HYDROXYLATED ALKALOIDS IN CRINUM-AUGUSTUM [J].
ALI, AA ;
KATING, H ;
FRAHM, AW ;
ELMOGHAZI, AM ;
RAMADAN, MA .
PHYTOCHEMISTRY, 1981, 20 (05) :1121-1123
[2]
Outbreak of severe acute respiratory syndrome in Hong kong special administrative region: case report [J].
Chan-Yeung, M ;
Yu, WC .
BRITISH MEDICAL JOURNAL, 2003, 326 (7394) :850-+
[3]
Treatment of SARS with human interferons [J].
Cinatl, J ;
Morgenstern, B ;
Bauer, G ;
Chandra, P ;
Rabenau, H ;
Doerr, HW .
LANCET, 2003, 362 (9380) :293-294
[4]
Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus [J].
Cinatl, J ;
Morgenstern, B ;
Bauer, G ;
Chandra, P ;
Rabenau, H ;
Doerr, HW .
LANCET, 2003, 361 (9374) :2045-2046
[5]
Cortese I, 1983, Boll Soc Ital Biol Sper, V59, P1261
[6]
USE OF AN AQUEOUS SOLUBLE TETRAZOLIUM FORMAZAN ASSAY FOR CELL-GROWTH ASSAYS IN CULTURE [J].
CORY, AH ;
OWEN, TC ;
BARLTROP, JA ;
CORY, JG .
CANCER COMMUNICATIONS, 1991, 3 (07) :207-212
[7]
Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong [J].
Donnelly, CA ;
Ghani, AC ;
Leung, GM ;
Hedley, AJ ;
Fraser, C ;
Riley, S ;
Abu-Raddad, LJ ;
Ho, LM ;
Thach, TQ ;
Chau, P ;
Chan, KP ;
Lam, TH ;
Tse, LY ;
Tsang, T ;
Liu, SH ;
Kong, JHB ;
Lau, EMC ;
Ferguson, NM ;
Anderson, RM .
LANCET, 2003, 361 (9371) :1761-1766
[8]
Identification of a novel coronavirus in patients with severe acute respiratory syndrome [J].
Drosten, C ;
Günther, S ;
Preiser, W ;
van der Werf, S ;
Brodt, HR ;
Becker, S ;
Rabenau, H ;
Panning, M ;
Kolesnikova, L ;
Fouchier, RAM ;
Berger, A ;
Burguière, AM ;
Cinatl, J ;
Eickmann, M ;
Escriou, N ;
Grywna, K ;
Kramme, S ;
Manuguerra, JC ;
Müller, S ;
Rickerts, V ;
Stürmer, M ;
Vieth, S ;
Klenk, HD ;
Osterhaus, ADME ;
Schmitz, H ;
Doerr, HW .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (20) :1967-1976
[9]
HONG SH, 1964, ACTA PHARMACOL SIN, V11, P1
[10]
Ieven M., 1982, J NAT PRODUCTS, V45, P564